Evaluation of leukapheresis and leukapheresis with additional cytoreduction in acute leukemia with hyperleukocytosis

Abstract

Background Hyperleukocytosis is a high-mortality emergency that must be diagnosed and treated promptly. The treatment options are low-dose cytosine arabinoside, hydroxyurea, steroids and leukapheresis. The risks and benefits of leukapheresis and leukapheresis with cytoreductive drugs in hyperleukocytosis are unclear. Therefore, we aimed to evaluate the efficacy of leukapheresis and the effect of adding cytoreductive drugs to leukapheresis in reducing leukocyte count and mortality in our patients. Material and Methods Thirty-four adult patients with acute leukaemia who underwent leukapheresis were included in this retrospective study. Results The median age was 66.5 years old, and 88.2% of the patients were acute myeloid leukaemia. The total number of leukapheresis was 69 cycles, and the median number of the procedure was 2. The most common symptoms were associated with the pulmonary system (67.6%). The median follow-up was 17.5 days. The mean reduction of leukocyte count was 69,112/mm3, and the efficacy of leukapheresis was 40.9%. The decrease in leukocyte and platelet counts was statistically significant when compared before and after leukapheresis. The mortality rate was 76.5% during hospitalization. While 24 patients received concomitant cytoreductive drugs with leukapheresis, ten did not. There was no statistically significant difference between these groups regarding reducing leukocyte count, efficiency of leukapheresis and mortality (p values 0.857, 0.562 and 0.553). Conclusions In our study, we showed the efficacy of leukapheresis in hyperleukocytosis but failed to show any difference in leukocyte reduction or mortality with additional cytoreductive drugs. Leukapheresis with concomitant cytoreduction does not abolish or increase mortality.

Keywords

• Acute leukemia
• hyperleukocytosis
• leukapheresis
• cytoreduction
• efficiency
• mortality

References

1. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015 May 21;125(21):3246-52. doi: 10.1182/blood-2014-10-551507.
2. Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001 Jun;42(1-2):67-73. doi: 10.3109/10428190109097677.
3. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: Practice management. Blood Rev. 2012 May;26(3):117-22. doi: 10.1016/j.blre.2012.01.003.
4. Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012 Sep 6;120(10):1993-2002. doi: 10.1182/blood-2012-04-424440.
5. Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020 May;61(5):1220-1225. doi: 10.1080/10428194.2020.1728753.
6. Zhang D, Zhu Y, Jin Y, Kaweme NM, Dong Y. Leukapheresis and hyperleukocytosis, past and future. Int J Gen Med. 2021 Jul 14;14:3457-67. doi: 10.2147/IJGM.S321787.
7. Macaron W, Sargsyan Z, Sahort NJ. Hyeprleukocytosis and leukostasis in acute and chronic leukemias. Leuk Lymphoma. 2022 Aug;63(8):1780-91. doi: 10.1080/10428194.2022.2056178.
8. Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, McCarthy LJ. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000 Sep;39(1-2):1-18. doi: 10.3109/10428190009053534.

9. Villgran V, Agha M, Raptis A, Hou JZ, Farah R, Lim SH, Redner RL, Im A, Sehgal A, Dorritie KA, Kiss JE, Normolle D, Boyiadzis M. Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Transfus Apher Sci. 2016 Oct;55(2):216-20. doi: 10.1016/j.transci.2016.07.001.
10. Bruserud Ø, Liseth K, Stamnesfet S, Cacic DL, Melve G, Kristoffersen E, Hervig T, Reikvam H. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single Centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus Med. 2013 Dec;23(6):397-406. doi: 10.1111/tme.12067.
11. Berber I, Erkurt MA, Kuku I, Kaya E, Gozukara Bag H, Nizam I, Koroglu M, Yigit A, Ozgul M. Leukapheresis treatment in elderly acute leukemia patients with hyperleukocytosis: A single center experience. J Clin Apher. 2016 Feb;31(1):53-8. doi: 10.1002/jca.21402.
12. Giammarco S, Chiusolo P, Piccirillo N, Di Giovanni A, Metafuni E, Laurenti L, Sica S, Pagano L. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017 Feb;10(2):147-54. doi: 10.1080/17474086.2017.1270754.
13. Powell BL, Gregory BW, Evans JK, White JC, Lyerly ES, Chorley HM, Russell GB, Capizzi RL. Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia. 1991 Dec;5(12):1037-42.
14. Choi MH, Choe YH, Park Y, Nah H, Kim S, Jeong SH, Kim HO. The effect of therapeuticleukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion. 2018 Jan;58(1):208-16. doi: 10.1111/trf.14329.
15. Wong GC. Hyperleukocytosis in acute myeloid leukemia patient is associated with high 30-day mortality which is not improved with leukapheresis. Ann Hematol. 2015 Dec;94(12):2067-8. doi: 10.1007/s00277-015-2472-2.
16. Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 Dec;34(12):3149-60. doi: 10.1038/s41375-020-0783-3.
17. Chang MC, Chen TY, Tang JL, Lan YJ, Chao TY, Chiu CF, Ho HT. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: No impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007 Nov;82(11):976-80. doi: 10.1002/ajh.20939.
18. Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D, Ottmann OG. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007 Oct;47(10):1843-50. doi: 10.1111/j.1537-2995.2007.01406.x.
19. Zhang X, Tu Y, Shen J, Feng Y, Ma H, Bai L, Li X, Lin Z, Dai L, Gong F, Lu T, Zhou J, Chen H, Lv Q, Zhu Z, Ruan C. Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study. Leuk Lymphoma. 2022 Nov;63(11):2636-44. doi: 10.1080/10428194.2022.2086246.
20. Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, Patriquin CJ, Pham HP, Sanchez AP, Schneiderman J, Witt V, Zantek ND, Dunbar NM. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023 Apr;38(2):77-278. doi: 10.1002/jca.22043.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
22. Lee H, Park S, Yoon JH, Cho BS, Kim HJ, Lee S Kim DW, Chung NG, Cho B, Kim KB, Yoo J, Jekarl DW, Chae H, Lim J, Kim M, Oh EJ, Kim Y. The factors influencing clinical outcomes after leukapheresis in acute leukaemia. Sci Rep. 2021 Mar 19;11(1):6426. doi: 10.1038/s41598-021-85918-8.
23. Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-a systematic review and meta-analysis. Transfusion. 2020 Oct;60(10):2360-9. doi: 10.1111/trf.15994.
24. Balogun RA, Sanchez AP, Klingel R, Witt V, Aqui N, Meyer E, Padmanabhan A, Pham HP, Schneiderman J, Schwartz J, Wu Y, Zantek ND, Connelly-Smith L, Dunbar NM. Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitis. J Clin Apher. 2020 Sep;35(5):493-9. doi: 10.1002/jca.21820.
25. Nguyen T, Bach K, Vu H, Nguyen NQ, Duong TD, Reys SD, Wheeler J. Pre-chemotherapy white blood cell depletion by therapeutic leukocytapheresis in leukemia patients: a single-institution experience. J Clin Apher. 2020 Apr;35(2):117-24. doi: 10.1002/jca.21766.
26. Jin Y, Guo S, Cui Q, Chen S, Liu X, Wei Y, Pan Y, Tang L, Huang T, Shen H, Xu G, Zuo X, Liu S, Xiao H, Chen F, Gong F, Zhou F. A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia. Sci Rep. 2018 Jan 10;8(1):294. doi: 10.1038/s41598-017-17534-4.
27. Rosales M, Roncon S, Mariz M, Ferreira AM, Faria F, Santos L. Therapeutic leukapheresis: experience of a single oncologic centre. Transfus Med Hemother. 2022 Feb 1;49(4):250-7. doi: 10.1159/000520933.
28. Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014 Apr 14;9(4):e95062. doi: 10.1371/journal.pone.0095062.
29. Oberoi S, Lehrnbecher T, Phillips B, Hitzler J, Ethier MC, Beyene J, Sung L. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systemic review and meta-analysis. Leuk Res. 2014 Apr;38(4):460-8. doi: 10.1016/j.leukres.2014.01.004.
30. Mamez AC, Raffoux E, Chevret S, Lemiale V, Boissel N, Canet E, Schlemmer B, Dombret H, Azoulay E, Lengline E. Pre-treatment with oral hydroxyurea prior to intensive chemotherapyimproves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leuk Lymphoma. 2016 Oct;57(10):2281-8. doi: 10.3109/10428194.2016.1142083.
31. Sharma K, Rao S, Bhat S. Effect of hydroxyurea on blood viscosity in chronic myelogenous leukemia with hyperleukocytosis. Physiol Chem Phys Med NMR. 1991;23(4):261-8.
32. Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997 Aug;98(2):433-6. doi: 10.1046/j.1365-2141.1997.1943011.x.
33. Nan X, Quin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, Iyer S. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis-a retrospective study from a tertiary center. Leuk Lymphoma. 2017 Sep;58(9):1-11. doi: 10.1080/10428194.2016.1277386.
34. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77. doi: 10.1182/blood.2022016867.